Agency Information Collection Activities: Submission for OMB Review; Comment Request, 61123-61124 [2024-16738]
Download as PDF
<![CDATA[
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 146 / Tuesday, July 30, 2024 / Notices
Responses: 1,275,912; Total Annual
Hours: 298,777. (For policy questions
regarding this collection contact
Da’Vona Boyd at 410–786–7483).
2. Type of Information Collection
Request: Revision of an approved
information collection; Title of
Information Collection: Improper
Payment Pre-Testing and Assessment
(IPPTA) Data Request Form; Use: To
comply with the Payment Integrity
Information Act of 2019 (PIIA), HHS
finalized the IPPTA to prepare State
Exchanges for the measurement of
improper payments of advance
payments of the premium tax credit
(APTC), to test processes and
procedures that support HHS’s review
of determinations of APTC made by
State Exchanges, and to provide a
mechanism for HHS and State
Exchanges to share information that
would aid in developing an efficient
measurement process. The PIIA requires
executive agencies to report on Federal
programs susceptible to significant
improper payments. The APTC program
was identified as a Federal program
susceptible to significant improper
payments. Currently in operation are 19
State Exchanges, which do not use the
Federal platform to perform eligibility
and enrollment determinations. Each
State Exchange was selected to
participate in the IPPTA data collection
for a period of 2 calendar years, which
began in 2024 or will begin in 2025
depending on which group the State
Exchange is assigned. HHS has revised
the approved data request form to
include new instructions and a data
mapping tool to aid State Exchanges in
their understanding and collecting of
necessary data. This collection of data
and data documentation is intended to
allow HHS to test the data elements as
specified in the scenarios provided to
each State Exchange in the pre-testing
and assessment data request form to
enable HHS to comply with the
requirements of the Payment Integrity
Information Act of 2019 (PIIA) and
implementing guidance. Form Number:
CMS–10829 (OMB control number:
0938–1439); Frequency: Annually;
Affected Public: State, Local, and
Federal Government; Number of
Respondents: 11; Number of Responses:
11; Total Annual Hours: 265. (For
policy questions regarding this
collection contact Halina DeSantis at
410–786–1000).
William N. Parham, III,
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–16736 Filed 7–29–24; 8:45 am]
BILLING CODE 4120–01–P
VerDate Sep<11>2014
16:51 Jul 29, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[Document Identifiers: CMS–10437]
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, and to allow
a second opportunity for public
comment on the notice. Interested
persons are invited to send comments
regarding the burden estimate or any
other aspect of this collection of
information, including the necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions, the accuracy of
the estimated burden, ways to enhance
the quality, utility, and clarity of the
information to be collected, and the use
of automated collection techniques or
other forms of information technology to
minimize the information collection
burden.
SUMMARY:
Comments on the collection(s) of
information must be received by the
OMB desk officer by August 29, 2024.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
To obtain copies of a supporting
statement and any related forms for the
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
DATES:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
61123
FOR FURTHER INFORMATION CONTACT:
William Parham at (410) 786–4669.
Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. The term ‘‘collection of
information’’ is defined in 44 U.S.C.
3502(3) and 5 CFR 1320.3(c) and
includes agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal agencies
to publish a 30-day notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension or
reinstatement of an existing collection
of information, before submitting the
collection to OMB for approval. To
comply with this requirement, CMS is
publishing this notice that summarizes
the following proposed collection(s) of
information for public comment:
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Generic Social
Marketing & Consumer Testing
Research; Use: The purpose of this
submission is to extend the approval of
the generic clearance for a program of
consumer research aimed at a broad
audience of those affected by CMS
programs including Medicare,
Medicaid, Children’s Health Insurance
Program (CHIP), and health insurance
exchanges. This program extends
strategic efforts to reach and tailor
communications to beneficiaries,
caregivers, providers, stakeholders, and
any other audiences that would support
the Agency in improving the
functioning of the health care system,
improve patient care and outcomes, and
reduce costs without sacrificing quality
of care. The information collected will
be used to create a streamlined and
proactive process for collection of data
and utilizing the feedback on service
delivery for continuous improvement of
communication activities aimed at
diverse CMS audiences. The generic
clearance will allow rapid response to
inform CMS initiatives using a mixture
of qualitative and quantitative consumer
research strategies (including formative
research studies and methodological
tests) to improve communication with
key CMS audiences. As new
information resources and persuasive
technologies are developed, they can be
tested and evaluated for beneficiary
response to the materials and delivery
SUPPLEMENTARY INFORMATION:
E:\FR\FM\30JYN1.SGM
30JYN1
61124
Federal Register / Vol. 89, No. 146 / Tuesday, July 30, 2024 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
channels. Results will inform
communication development and
information architecture as well as
allow for continuous quality
improvement. The overall goal is to
maximize the extent to which
consumers have access to useful sources
of CMS program information in a form
that can help them make the most of
their benefits and options. The activities
under this clearance involve social
marketing and consumer research using
samples of self-selected customers, as
well as convenience samples, and quota
samples, with respondents selected
either to cover a broad range of
customers or to include specific
characteristics related to certain
products or services. All collection of
information under this clearance will
utilize a subset of items drawn from a
core collection of customizable items
referred to as the Social Marketing and
Consumer Testing Item Bank. This item
bank is designed to establish a set of
pre-approved generic question that can
be drawn upon to allow for the rapid
turn-around consumer testing required
for us to communicate more effectively
with our audiences. The questions in
the item bank are divided into two
major categories. One set focuses on
characteristics of individuals and is
intended primarily for participant
screening and for use in structured
quantitative on-line or telephone
surveys. The other set is less structured
and is designed for use in qualitative
one-on-one and small group discussions
or collecting information related to
subjective impressions of test materials.
Results will be compiled and
disseminated so that future
communication can be informed by the
testing results. We will use the findings
to create the greatest possible public
benefit. Form Number: CMS–10437
(OMB control number: 0938–1247);
Frequency: Yearly; Affected Public:
Individuals; Number of Respondents:
7,732; Number of Responses: 61,992;
Total Annual Hours: 26,688. (For policy
questions regarding this collection
contact Hemalgiri Gosai at 410–786–
0000.)
William N. Parham, III,
Director, Division of Information Collections
and Regulatory Impacts, Office of Strategic
Operations and Regulatory Affairs.
[FR Doc. 2024–16738 Filed 7–29–24; 8:45 am]
BILLING CODE 4120–01–P
VerDate Sep<11>2014
16:51 Jul 29, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–1768]
Advisory Committee; Pharmacy
Compounding Advisory Committee;
Renewal
AGENCY:
Food and Drug Administration,
HHS.
Notice; renewal of Federal
advisory committee.
ACTION:
The Food and Drug
Administration (FDA or the Agency) is
announcing the renewal of the
Pharmacy Compounding Advisory
Committee by the Commissioner of
Food and Drugs (the Commissioner).
The Commissioner has determined that
it is in the public interest to renew the
Pharmacy Compounding Advisory
Committee for an additional 2 years
beyond the charter expiration date. The
new charter will be in effect until the
April 25, 2026, expiration date.
DATES: Authority for the Pharmacy
Compounding Advisory Committee will
expire on April 25, 2026, unless the
Commissioner formally determines that
renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT:
Takyiah Stevenson, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 240–
402–2507, PCAC@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to 41 CFR 102–3.65 and approval by the
Department of Health and Human
Services and by the General Services
Administration, FDA is announcing the
renewal of the Pharmacy Compounding
Advisory Committee (the Committee).
The Committee is a non-discretionary
Federal advisory committee established
to provide advice to the Commissioner.
The Committee advises the
Commissioner or designee in
discharging responsibilities as they
relate to compounding drugs for human
use and, as required, any other product
for which FDA has regulatory
responsibility.
The Committee shall provide advice
on scientific, technical, and medical
issues concerning drug compounding
under sections 503A and 503B of the
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 353a and 353b), and, as
required, any other product for which
FDA has regulatory responsibility and
make appropriate recommendations to
the Commissioner.
Pursuant to its charter, the Committee
shall consist of a core of 12 voting
SUMMARY:
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
members including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
authorities knowledgeable in the fields
of pharmaceutical compounding,
pharmaceutical manufacturing,
pharmacy, medicine, and related
specialties. These members will include
representatives from the National
Association of Boards of Pharmacy, the
United States Pharmacopeia,
pharmacists with current experience
and expertise in compounding,
physicians with background and
knowledge in compounding, and patient
and public health advocacy
organizations. Members will be invited
to serve for overlapping terms of up to
4 years.
Non-Federal members of this
committee will serve as Special
Government Employees,
representatives, or Ex-Officio members.
Federal members will serve as Regular
Government Employees or Ex-Officios
members. The core of voting members
may include one or more technically
qualified members, selected by the
Commissioner or designee, who are
identified with consumer interests and
are recommended by either a
consortium of consumer-oriented
organizations or other interested
persons. In addition to the voting
members, the Committee may include
one or more non-voting representative
members who are identified with
industry interests. There may also be an
alternate industry representative.
The Commissioner or designee shall
have the authority to select members of
other scientific and technical FDA
advisory committees (normally not to
exceed 10 members) to serve
temporarily as voting members and to
designate consultants to serve
temporarily as voting members when:
(1) expertise is required that is not
available among current voting standing
members of the Committee (when
additional voting members are added to
the Committee to provide needed
expertise, a quorum will be based on the
combined total of regular and added
members), or (2) to comprise a quorum
when, because of unforeseen
circumstances, a quorum is or will be
lacking. Because of the size of the
Committee and the variety in the types
of issues that it will consider, FDA may,
in connection with a particular
committee meeting, specify a quorum
that is less than a majority of the current
voting members. The Agency’s
regulations (21 CFR 14.22(d)) authorize
a committee charter to specify quorum
requirements.
If functioning as a medical device
panel, an additional non-voting
E:\FR\FM\30JYN1.SGM
30JYN1
]]>Agencies
[Federal Register Volume 89, Number 146 (Tuesday, July 30, 2024)]
[Notices]
[Pages 61123-61124]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-16738]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[Document Identifiers: CMS-10437]
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
AGENCY: Centers for Medicare & Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Medicare & Medicaid Services (CMS) is
announcing an opportunity for the public to comment on CMS' intention
to collect information from the public. Under the Paperwork Reduction
Act of 1995 (PRA), Federal agencies are required to publish notice in
the Federal Register concerning each proposed collection of
information, including each proposed extension or reinstatement of an
existing collection of information, and to allow a second opportunity
for public comment on the notice. Interested persons are invited to
send comments regarding the burden estimate or any other aspect of this
collection of information, including the necessity and utility of the
proposed information collection for the proper performance of the
agency's functions, the accuracy of the estimated burden, ways to
enhance the quality, utility, and clarity of the information to be
collected, and the use of automated collection techniques or other
forms of information technology to minimize the information collection
burden.
DATES: Comments on the collection(s) of information must be received by
the OMB desk officer by August 29, 2024.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function.
To obtain copies of a supporting statement and any related forms
for the proposed collection(s) summarized in this notice, please access
the CMS PRA website by copying and pasting the following web address
into your web browser: https://www.cms.gov/Regulations-and-Guidance/Legislation/PaperworkReductionActof1995/PRA-Listing.
FOR FURTHER INFORMATION CONTACT: William Parham at (410) 786-4669.
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), Federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. The term ``collection of
information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and
includes agency requests or requirements that members of the public
submit reports, keep records, or provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires
Federal agencies to publish a 30-day notice in the Federal Register
concerning each proposed collection of information, including each
proposed extension or reinstatement of an existing collection of
information, before submitting the collection to OMB for approval. To
comply with this requirement, CMS is publishing this notice that
summarizes the following proposed collection(s) of information for
public comment:
1. Type of Information Collection Request: Revision of a currently
approved collection; Title of Information Collection: Generic Social
Marketing & Consumer Testing Research; Use: The purpose of this
submission is to extend the approval of the generic clearance for a
program of consumer research aimed at a broad audience of those
affected by CMS programs including Medicare, Medicaid, Children's
Health Insurance Program (CHIP), and health insurance exchanges. This
program extends strategic efforts to reach and tailor communications to
beneficiaries, caregivers, providers, stakeholders, and any other
audiences that would support the Agency in improving the functioning of
the health care system, improve patient care and outcomes, and reduce
costs without sacrificing quality of care. The information collected
will be used to create a streamlined and proactive process for
collection of data and utilizing the feedback on service delivery for
continuous improvement of communication activities aimed at diverse CMS
audiences. The generic clearance will allow rapid response to inform
CMS initiatives using a mixture of qualitative and quantitative
consumer research strategies (including formative research studies and
methodological tests) to improve communication with key CMS audiences.
As new information resources and persuasive technologies are developed,
they can be tested and evaluated for beneficiary response to the
materials and delivery
[[Page 61124]]
channels. Results will inform communication development and information
architecture as well as allow for continuous quality improvement. The
overall goal is to maximize the extent to which consumers have access
to useful sources of CMS program information in a form that can help
them make the most of their benefits and options. The activities under
this clearance involve social marketing and consumer research using
samples of self-selected customers, as well as convenience samples, and
quota samples, with respondents selected either to cover a broad range
of customers or to include specific characteristics related to certain
products or services. All collection of information under this
clearance will utilize a subset of items drawn from a core collection
of customizable items referred to as the Social Marketing and Consumer
Testing Item Bank. This item bank is designed to establish a set of
pre-approved generic question that can be drawn upon to allow for the
rapid turn-around consumer testing required for us to communicate more
effectively with our audiences. The questions in the item bank are
divided into two major categories. One set focuses on characteristics
of individuals and is intended primarily for participant screening and
for use in structured quantitative on-line or telephone surveys. The
other set is less structured and is designed for use in qualitative
one-on-one and small group discussions or collecting information
related to subjective impressions of test materials. Results will be
compiled and disseminated so that future communication can be informed
by the testing results. We will use the findings to create the greatest
possible public benefit. Form Number: CMS-10437 (OMB control number:
0938-1247); Frequency: Yearly; Affected Public: Individuals; Number of
Respondents: 7,732; Number of Responses: 61,992; Total Annual Hours:
26,688. (For policy questions regarding this collection contact
Hemalgiri Gosai at 410-786-0000.)
William N. Parham, III,
Director, Division of Information Collections and Regulatory Impacts,
Office of Strategic Operations and Regulatory Affairs.
[FR Doc. 2024-16738 Filed 7-29-24; 8:45 am]
BILLING CODE 4120-01-P
